The role of primary RPLND in clinical stage IIA/B testicular germ cell tumor: a narrative review.

Parth Thakker, Connor Drake, Timothy Masterson, Clint Cary

Abstract readReview

In one paragraph

Review in Urologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Parth ThakkerDepartment of Urology, Indiana University School of Medicine, 340 W 10th St, 46202, Indianapolis, IN, USA. puthakke@iu.edu.

Connor DrakeDepartment of Urology, Indiana University School of Medicine, 340 W 10th St, 46202, Indianapolis, IN, USA.

Timothy MastersonDepartment of Urology, Indiana University School of Medicine, 340 W 10th St, 46202, Indianapolis, IN, USA.

Clint CaryDepartment of Urology, Indiana University School of Medicine, 340 W 10th St, 46202, Indianapolis, IN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retroperitoneal lymph node dissection (RPLND) plays a critical role in the multidisciplinary management of advanced testicular cancer. Cisplatin-based chemotherapy regimens have been the cornerstone of treatment for these patients. Long-term toxicity and secondary malignancy in patients receiving cisplatin, along with surgical advancements, have encouraged providers to revisit the role of primary RPLND for patients with stage IIA/B germ cell tumor. Nerve-sparing primary RPLND offers durable oncologic outcomes without the long-term comorbidities associated with chemotherapy. The focus of this review is to summarize the published data on primary RPLND for stage IIA/B germ cell tumors, to identify the ideal patient population for this treatment modality, and to explore the future of surgical advancements.

Indexed as

Lymph Node ExcisionNeoplasms, Germ Cell and EmbryonalTesticular NeoplasmsHumansMaleNeoplasm StagingRetroperitoneal SpaceTreatment OutcomeGerm cell tumorPrimary retroperitoneal lymph node dissectionRelapseSecondary malignancySeminoma/nonseminoma

Identifiers

PMID40748382

DOI10.1007/s00120-025-02648-9

PMCPMC12669368

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.